Table 5.
Cox Proportional Hazards Analyses Determining the Factors Related With the Overall Survival Rate Among Patients Who Received Atezo/Bev as Their First-Line Therapy
| Characteristic | Univariate analysis (Wilcoxon) |
Multivariate analysis (Cox) |
||
|---|---|---|---|---|
| P value | Hazard ratio | 95% CI | P value | |
| Age | ||||
| ≥73 | .734 | |||
| Sex | ||||
| Male/female | .216 | |||
| ECOG performance status | ||||
| >0 | .552 | |||
| Etiology of HCC | ||||
| NASH/others | .265 | |||
| Child-Pugh score | ||||
| >5 | .075 | |||
| PLT | ||||
| ≥16.8 | .526 | |||
| NLR | ||||
| ≥2.7 | .303 | 7.10 | 1.61–31.2 | .009a |
| T-BiL | ||||
| ≥0.79 | .273 | |||
| Albumin | ||||
| <3.8 | .003a | 14.2 | 2.38–84.94 | .003a |
| Cr | ||||
| ≥0.74 | .699 | |||
| Ferritin | ||||
| ≥169 | .254 | |||
| PT-INR | ||||
| ≥1.06 | .909 | |||
| AFP | ||||
| ≥114 | .383 | |||
| DCP | ||||
| ≥350 | .119 | |||
| Anti-PD-1 autoantibody | ||||
| ≥0.57 | .045a | 7.82 | 1.54–39.6 | .013a |
| Distant metastasis | ||||
| Present/absent | .306 | |||
| Vascular invasion | ||||
| Present/absent | .665 | |||
| BCLC stage | ||||
| A, B/C | .256 | |||
| Prior local therapy | ||||
| Present/absent | .275 | |||
| Protocols for the second line and subsequent therapies | ||||
| Present/absent | .198 | |||
AFP, alfa-fetoprotein; Anti-PD-1, autoantibody, anti-programmed cell death-1, autoantibody; BCLC, Barcelona Clinic Liver Cancer; Cr, creatinine; DCP, des-γ-carboxy prothrombin; ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma; NASH, nonalcoholic steatohepatitis; NLR, neutrophil lymphocyte ratio; PLT, platelets; PT-INR, prothrombin time-international normalized ratio; T-BIL, total bilirubin.
a
P < .05.